Liraglutide

The safety profile of liraglutide is derived from multiple clinical trials and observational studies, though several specific safety considerations require further investigation.

Known Side Effects

Evidence is limited in the provided studies regarding comprehensive side effect profiles. The available research suggests that liraglutide is generally well-tolerated in clinical trial settings, but detailed adverse event data is not extensively reported in the evidence provided.

Contraindications

The evidence provided does not contain sufficient information to definitively outline absolute contraindications for liraglutide. This represents a significant gap in the available evidence for this safety assessment.

Drug Interactions

Based on the clinical trials referenced, liraglutide has been studied in combination with several medications:

• Metformin: Multiple phase 3 and 4 trials demonstrate concurrent use with metformin
• Insulin: Studies show co-administration with insulin glargine and combination products (IDegLira)
• SGLT2 inhibitors: Network meta-analysis suggests concurrent use is being evaluated
• Other oral antidiabetic agents (OADs): Phase 4 trials indicate combination therapy is practiced

However, the evidence provided does not detail specific drug interaction mechanisms or contraindicated combinations.

Special Populations

Reproductive Health

Emerging evidence suggests potential effects on reproductive health:

• One study examined associations between GLP-1 receptor agonists (including liraglutide) and menstrual events in reproductive-aged patients
• Research is investigating fertility effects, though the evidence regarding safety in pregnancy and fertility is limited

Cardiovascular Considerations

A network meta-analysis examined cardiovascular safety, specifically ventricular arrhythmias and cardiovascular events, but detailed safety conclusions are not provided in the available evidence.

Limitations and Evidence Gaps

The evidence provided has significant limitations for a comprehensive safety assessment:

• Specific adverse event rates and severity classifications are not detailed
• Long-term safety data beyond 104 weeks is not extensively covered
• Safety in pediatric populations is not addressed
• Detailed contraindication criteria are not provided
• Specific drug interaction mechanisms are not described

Disclaimer: This safety information is based solely on the limited evidence provided and should not replace consultation with healthcare providers. Patients should discuss their individual risk factors and medical history with their physician before starting liraglutide therapy.

Clinical judgment and additional prescribing information should be consulted for complete safety guidance, as the evidence reviewed here provides only a partial picture of liraglutide's safety profile.